IRVING, Texas--(BUSINESS WIRE)--For the eighth consecutive year, McKesson has received approval from the Centers for Medicare & Medicaid Services (CMS)…
IRVING, Texas--(BUSINESS WIRE)--For the eighth consecutive year, McKesson has received approval from the Centers for Medicare & Medicaid Services (CMS)…
JACKSON CENTER, PA / ACCESSWIRE / February 8, 2024 / Halberd Corporation's (OTC PINK:HALB) Traumatic Brain Injury (TBI) mitigating nasal…
ANN ARBOR, MI / ACCESSWIRE / February 8, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary…
• Initial clinical data suggest the potential of B-VEC to treat lesions in the eye of DEB patients and additional…
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and…
SUNNYVALE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (“BioCardia” or the “Company”) (Nasdaq: BCDA), a biotechnology company focused on…
CAMBRIDGE, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new…
—Company receives FDA IND clearance for the development of enobosarm in combination with GLP-1 drugs for potentially higher quality weight…
VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse…